Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

26 Oct 2023

Abstract excerpt

Background: CDK4/6 inhibitors (CDK4/6i) have been established as standard treatment against advanced Estrogen Receptor-positive breast cancers. These drugs are being tested against several cancers, including in combinations with other therapies. We identified the T172-phosphorylation of CDK4 as the step determining its activity, retinoblastoma protein (RB) inactivation, cell cycle commitment and sensitivity to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37964967
DOI: 10.3389/fendo.2023.1247542

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomasPMID 37964967Read ↗

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomasSemantic proximity Read ↗

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclibSemantic proximity Read ↗

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.Semantic proximity Read ↗

Absence of phosphorylated CDK4, a biomarker of intrinsic resistance to CDK4/6 inhibitors in head and neck squamous cell carcinoma, can be predicted by their gene expression profileSemantic proximity Read ↗

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibitionSemantic proximity Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.Semantic proximity Read ↗

Molecular Pathways: CDK4 Inhibitors for Cancer TherapySemantic proximity Read ↗

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapySemantic proximity Read ↗

Targeting CDK4/6 in patients with cancerSemantic proximity Read ↗

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer TreatmentSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.